OF IMPROVING LIVES

                              Our employees are focused on putting science, technology and innovation to work to make a difference in patients' lives. This effort starts in the labs, moves into the clinic and continues with our commitment to ensuring patients can access the therapies they need.

                              PATIENT SUPPORT PROGRAMS

                              Regeneron offers the comprehensive patient programs DUPIXENT MyWay, EYLEA4U, KevzaraConnect, LIBTAYO Surround and MyPraluent, to help eligible patients throughout their treatment journey with insurance eligibility support, patient resources, financial assistance and access to free medicine.

                              • DUPIXENT MyWay? logo
                              • EYLEA4U? logo
                              • KevzaraConnect? logo
                              • LIBTAYO Surround logo
                              • MyPRALUENT? logo
                              Regeneron's Compassionate Use policy demonstrates their commitment to bringing new medicines to people with serious diseases.

                              REGENERON COMPASSIONATE USE POLICY

                              We are committed to bringing important new medicines to people with serious diseases.

                              Before a new treatment is widely available to the public, it undergoes years of rigorous clinical testing to satisfy the safety and efficacy criteria required for regulatory approval. Approval by a country or region's health regulatory authority, such as the U.S. Food and Drug Administration, allows the appropriate group of people to access a medicine.

                              In some cases, a potentially beneficial therapy may not yet be approved by regulatory authorities. Therefore, Regeneron has established a Compassionate Use Policy to help provide access to an investigational medical product, with the required permission from a health regulatory authority.

                              LEARN MORE ABOUT
                              COMPASSIONATE USE REQUESTS

                              In the USA, this type of compassionate use program is also known as an Expanded Access Program (EAP) and is intended for patients with serious or life-threatening conditions who do not have any viable or available treatment options, and are unable to participate in ongoing clinical trials. To view a list of Regeneron’s open clinical trials, visit clinicaltrials.gov.

                              To ensure the safety of patients, we have developed certain criteria to evaluate Compassionate Use requests. All such requests are required to be in accordance with local laws and regulations, as well as with Regeneron Policies. While Regeneron is committed to reviewing each request carefully, fairly and on a case-by-case basis, we cannot guarantee access to any specific investigational medical product by any individual patient.

                              Requests for compassionate use must be initiated by a treating physician, so if you are a patient or caregiver, please ask your doctor for support in this process. Physicians should send compassionate use requests to CompassionateUse_Requests@regeneron.com. Regeneron will acknowledge receipt of a physician’s request within five business days.

                              The following criteria must be met for consideration of Compassionate Use request:

                              1. There is sufficient data to expect that the investigational medical product will have a favorable benefit-risk profile.
                              2. The regulatory agency in the country where the patient resides must also approve the proposed use of the investigational drug, when required.
                              3. Providing the investigational medical product will not interfere with or compromise its clinical development. This means that adequate supply of the investigational medical product must be available to perform necessary clinical studies before access is provided through the Compassionate Use program.
                              4. There is a legitimate medical need documented and submitted by the treating physician.
                              5. The physician initiating the Compassionate Use request and providing treatment must be qualified in terms of background, education, and experience to carry out the proposed protocol.
                              6. The initiating physician agrees to assume all responsibilities and obligations to comply with the relevant regulatory requirements.


                              PATIENT ADVOCACY

                              Regeneron is committed to supporting patients with serious diseases and ensuring that patients are able to access the medicines they need.

                              Bringing Attention to a Debilitating Disease

                              The Understand AD national initiative aims to increase awareness and understanding of atopic dermatitis (AD), in partnership with the National Eczema Association (NEA) and the Dermatology Nurses’ Association (DNA). The most common form of eczema, AD is a chronic inflammatory disease with symptoms often appearing as a rash on the skin. The initiative offers a glimpse into the daily struggle of life with AD and connects people to helpful resources such as the NEA.

                              Education & Awareness for Cholesterol Management

                              In 2016, Regeneron and Sanofi committed to support the American Heart Association’s cholesterol education program, Check.Change.Control.Cholesterol, which aims to drive millions of Americans to better cholesterol management. The three-year program will engage patients, caregivers and healthcare practitioners, and provide valuable educational resources to communities across the country.

                              Partnering to Fight a Rare Disease

                              Fibrodysplasia ossificans progressiva (FOP) is an exceedingly rare disease in which bone forms in the muscle and connective tissue. Over time, people living with FOP gradually lose the ability to move and even breathe as their rib cage loses flexibility. When Regeneron discovered that the protein Activin-A played a role in triggering FOP, we made it a priority to reach out to the small but strong FOP community to understand their daily struggles and treatment expectations. Since then, organizations such as the International Fibrodysplasia Ossificans Progressiva Association (IFOPA) and the National Organization for Rare Disorders (NORD) have been integral to informing the development of our investigational candidate REGN2477 and to helping us keep patient needs front and center in our efforts. We’ve also given back to the FOP community with grants and by sharing our genetically modified FOP mouse model with other scientists to advance basic and translational research. Through these mutually supportive relationships, we have come together with the FOP community to fight this devastating disease.

                              Regeneron ensures patients are able to access the medicines they need.